Whistleblower Can't Fight Amgen's $612M Aranesp Deal: Judge

Law360, New York (January 3, 2013, 4:09 PM EST) -- A New York federal judge on Wednesday denied a whistleblower's bid to challenge Amgen Inc.'s $612 million civil settlement over misbranding its Aranesp anemia drug, part of a combined $762 million in criminal and civil penalties shelled out by the biotech giant.

Dr. Joseph Piacentile, one of several people to launch qui tam suits accusing Amgen of violating the federal False Claims Act and similar state statutes by improperly promoting off-label use of Aranesp and giving doctors kickbacks to prescribe it to patients, said he didn't...
To view the full article, register now.

Related

Sections

Case Information

Case Title

United States of America, ex rel. Joseph Piacentile v. Amgen Inc. et al


Case Number

2:04-cv-03983

Court

New York Eastern

Nature of Suit

Other Statutory Actions

Judge

Sterling Johnson, Jr

Date Filed

September 14, 2004

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.